Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
PharmacoEconomics
Published in: PharmacoEconomics 1/2006

01-11-2006 | Original Research Article

Cost-effectiveness of Rosiglitazone Oral Combination for the Treatment of Type 2 Diabetes in Germany

Authors: Arran T. Shearer, Adrian Bagust, Andreas Liebl, Oliver Schoeffski, Anita Goertz

Published in: PharmacoEconomics | Special Issue 1/2006

Login to get access
Metadata
Title
Cost-effectiveness of Rosiglitazone Oral Combination for the Treatment of Type 2 Diabetes in Germany
Authors
Arran T. Shearer
Adrian Bagust
Andreas Liebl
Oliver Schoeffski
Anita Goertz
Publication date
01-11-2006
Publisher
Springer International Publishing
Published in
PharmacoEconomics / Issue Special Issue 1/2006
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI
https://doi.org/10.2165/00019053-200624001-00004

Other articles of this Special Issue 1/2006

PharmacoEconomics 1/2006 Go to the issue

Original Research Article

Cost-effectiveness of Rosiglitazone Combination Therapy for the Treatment of Type 2 Diabetes Mellitus in the UK

Introduction

Simulating the Real World of Antihyperglycaemic Therapies in Type 2 Diabetes

Original Research Article

A Model of Long-term Metabolic Progression of Type 2 Diabetes Mellitus for Evaluating Treatment Strategies

Original Research Article

Lifetime Health Consequences and Cost-effectiveness of Rosiglitazone in Combination with Metformin for the Treatment of Type 2 Diabetes in Spain